Frederic Triebel
Saint-aubin-les-forges, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Crystal structure of the human LAG-3-HLA-DR1-peptide complex.
Journal: Science immunology
Published: December 13, 2024
Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study.
Journal: JTO clinical and research reports
Published: May 13, 2024
Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 10, 2024
A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology.
Journal: ESMO open
Published: June 26, 2023
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 23, 2023
Immunophenotyping of Peripheral Blood Mononuclear Cells in Septic Shock Patients With High-Dimensional Flow Cytometry Analysis Reveals Two Subgroups With Differential Responses to Immunostimulant Drugs.
Journal: Frontiers in immunology
Published: November 27, 2020
Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma.
Journal: Journal for immunotherapy of cancer
Published: October 27, 2020
Molecular characterization of HLA class II binding to the LAG-3 T cell co-inhibitory receptor.
Journal: European journal of immunology
Published: May 15, 2020
A LAG-3-Specific Agonist Antibody for the Treatment of T Cell-Induced Autoimmune Diseases.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: July 16, 2019
AIPAC: a Phase IIb study of eftilagimod alpha (IMP321 or LAG-3Ig) added to weekly paclitaxel in patients with metastatic breast cancer.
Journal: Future oncology (London, England)
Published: April 13, 2019
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016.
Journal: Journal for immunotherapy of cancer
Published: March 27, 2017
Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 22, 2015
Last Updated: 09/26/2026